Table 2.
Measures of agreement and validity comparing reporting of chemotherapy in the Danish National Registry of Patients with the reference standard by hospital
| Treatment | Source of reporting
|
Sensitivity 95% CI | Specificity 95% CI | PPV 95% CI | NPV 95% CI | Kappa 95% CI | |||
|---|---|---|---|---|---|---|---|---|---|
| Ref Y DNRP Y |
Ref N DNRP N |
Ref Y DNRP N |
Ref N DNRP Y |
||||||
| Aarhus | |||||||||
| Chemotherapy | 17 | 7 | 1 | 0 | 0.94(0.84–1.00) | 1.00 | 1.00 | 0.87(0.65–1.00) | 0.90 (0.72– 1.00) |
| 5-FUa | 0 | 23 | 2 | 0 | 0.00 | 1.00 | – | 0.92(0.81–1.00) | – |
| Oxaliplatinb | 3 | 13 | 9 | 0 | 0.25 (0.05–0.50) | 1.00 | 1.00 | 0.59 (0.39–0.80) | 0.26 (0.00–0.52) |
| Bevacizumabc | 3 | 21 | 1 | 0 | 0.75(0.33–1.00) | 1.00 | 1.00 | 0.95(0.87–1.00) | 0.83 (0.52–1.00) |
| Aalborg | |||||||||
| Chemotherapy | 17 | 7 | 0 | 1 | 1.00 | 0.88(0.65–1.00) | 0.94(0.84–1.00) | 1.00 | 0.90(0.72–1.00) |
| 5-FUa | 8 | 16 | 0 | 1 | 1.00 | 0.94(0.83–1.00) | 0.89(0.68–1.00) | 1.00 | 0.91 (0.74–1.00) |
| Oxaliplatinb | 3 | 22 | 0 | 0 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Bevacizumabc | 6 | 19 | 0 | 0 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Notes:
a
Includes administration of 5-FU or capecitabine without oxaliplatin or bevacizumab;
b
Includes administration of oxaliplatin in combination with 5-FU (FOLFOX) or capecitabine (XELOX), but without bevacizumab
c
Includes administration of bevacizumab in combination with FOLFOX, XELOX, irinotecan and 5-FU (FOLFIRI), or 5-FU.
Abbreviations: CI, confidence interval; Ref, reference standard; Y, yes; N, no; DNRP, Danish National Registry of Patients; PPV, positive predictive value; NPV, negative predictive value; 5-FU, 5-fluorouracil.